Komarnicki, P.; Gut, P.; Cieślewicz, M.; Musiałkiewicz, J.; Maciejewski, A.; Czupińska, M.; Mastorakos, G.; Ruchała, M.
Serum β-hCG as a Biomarker in Pancreatic Neuroendocrine Tumors: Rethinking Single-Analyte Approach. Cancers 2024, 16, 2060.
https://doi.org/10.3390/cancers16112060
AMA Style
Komarnicki P, Gut P, Cieślewicz M, Musiałkiewicz J, Maciejewski A, Czupińska M, Mastorakos G, Ruchała M.
Serum β-hCG as a Biomarker in Pancreatic Neuroendocrine Tumors: Rethinking Single-Analyte Approach. Cancers. 2024; 16(11):2060.
https://doi.org/10.3390/cancers16112060
Chicago/Turabian Style
Komarnicki, Paweł, Paweł Gut, Maja Cieślewicz, Jan Musiałkiewicz, Adam Maciejewski, Michalina Czupińska, George Mastorakos, and Marek Ruchała.
2024. "Serum β-hCG as a Biomarker in Pancreatic Neuroendocrine Tumors: Rethinking Single-Analyte Approach" Cancers 16, no. 11: 2060.
https://doi.org/10.3390/cancers16112060
APA Style
Komarnicki, P., Gut, P., Cieślewicz, M., Musiałkiewicz, J., Maciejewski, A., Czupińska, M., Mastorakos, G., & Ruchała, M.
(2024). Serum β-hCG as a Biomarker in Pancreatic Neuroendocrine Tumors: Rethinking Single-Analyte Approach. Cancers, 16(11), 2060.
https://doi.org/10.3390/cancers16112060